Published in Eur Heart J on December 01, 2002
Choice and place of death: individual preferences, uncertainty, and the availability of care. J R Soc Med (2007) 1.88
Review article: a model of palliative care for heart failure. Am J Hosp Palliat Care (2009) 1.85
Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. Heart (2006) 1.84
Immunological mechanisms of pentoxifylline in chronic heart failure. Eur J Heart Fail (2009) 1.81
A propensity matched study of New York Heart Association class and natural history end points in heart failure. Am J Cardiol (2006) 1.52
Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. Am Heart J (2006) 1.32
Predictors of readmission and health related quality of life in patients with chronic heart failure: a comparison of different psychosocial aspects. J Behav Med (2010) 1.11
Rationale, design and conduct of a randomised controlled trial evaluating a primary care-based complex intervention to improve the quality of life of heart failure patients: HICMan (Heidelberg Integrated Case Management). BMC Cardiovasc Disord (2007) 1.04
Patients' self-assessed functional status in heart failure by New York Heart Association class: a prognostic predictor of hospitalizations, quality of life and death. J Card Fail (2009) 1.02
The fine art of prognostication. Eur Heart J (2002) 0.87
Miniaturization of mechanical circulatory support systems. Artif Organs (2012) 0.87
A propensity-matched study of the association of physical function and outcomes in geriatric heart failure. Arch Gerontol Geriatr (2007) 0.86
Development of an economic model to assess the cost-effectiveness of hawthorn extract as an adjunct treatment for heart failure in Australia. BMJ Open (2012) 0.84
Type D personality is a predictor of poor emotional quality of life in primary care heart failure patients independent of depressive symptoms and New York Heart Association functional class. J Behav Med (2010) 0.84
Exploring the perspectives and preferences for HTA across German healthcare stakeholders using a multi-criteria assessment of a pulmonary heart sensor as a case study. Health Res Policy Syst (2015) 0.81
Early feasibility testing and engineering development of the transapical approach for the HeartWare MVAD ventricular assist system. ASAIO J (2014) 0.80
A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptoms. Heart Fail Rev (2015) 0.78
Comparison of predictors of heart failure-related hospitalization or death in patients with versus without preserved left ventricular ejection fraction. Am J Cardiol (2013) 0.78
The causes, consequences, and treatment of left or right heart failure. Vasc Health Risk Manag (2011) 0.77
Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people. Eur J Heart Fail (2016) 0.76
New information about resynchronisation. Neth Heart J (2003) 0.75
Factors associated with β-blocker initiation and discontinuation in a population-based cohort of seniors newly diagnosed with heart failure. Patient Prefer Adherence (2016) 0.75
Results of a heart failure outpatient clinic in a non-university hospital with a two-year follow-up. Neth Heart J (2003) 0.75
The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J (2003) 4.09
Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J (2003) 3.78
The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J (2003) 2.78
Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J (2004) 2.73
The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina. Eur Heart J (2002) 2.68
Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet (2002) 2.61
Serum level monitoring of antibacterial drugs. A review. Clin Pharmacokinet (1985) 2.01
Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine. Br J Clin Pharmacol (2000) 1.82
Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS) J Am Coll Cardiol (1990) 1.76
Management of patients with heart failure in clinical practice: differences between men and women. Heart (2007) 1.73
Intravenous cyclosporine kinetics in renal failure. Clin Pharmacol Ther (1983) 1.73
Langerhans'-cell histiocytosis in adults. Med Pediatr Oncol (1997) 1.62
Is blood pressure response to the Valsalva maneuver related to neurohormones, exercise capacity, and clinical findings in heart failure? Chest (1999) 1.40
Coronary thrombectomy by retrieval of an open emboli-protection filter device. Heart (2008) 1.39
Long term follow up of prosthetic valve endocarditis: what characteristics identify patients who were treated successfully with antibiotics alone? Heart (1999) 1.26
Theophylline serum concentration and therapeutic effect in severe acute bronchial obstruction: the optimal use of intravenously administered aminophylline. Am Rev Respir Dis (1982) 1.18
Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol (1995) 1.16
Multicompartment pharmacokinetics of netilmicin. Eur J Clin Pharmacol (1979) 1.16
Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol (1998) 1.12
Drug-induced pulmonary hypertension? Br Med J (1971) 1.12
Lethal autoimmune myocarditis in interferon-gamma receptor-deficient mice: enhanced disease severity by impaired inducible nitric oxide synthase induction. Circulation (2001) 1.10
Influence of chronic dosing on theophylline clearance. Br J Clin Pharmacol (1985) 1.07
Population pharmacokinetics of tobramycin. Br J Clin Pharmacol (1989) 1.07
Reliability of antiarrhythmic drug plasma concentration monitoring. Clin Pharmacokinet (1983) 1.00
Predicting individual phenytoin dosage. J Pharmacokinet Biopharm (1981) 0.98
Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine. Eur J Clin Pharmacol (1986) 0.96
Plasma concentration monitoring of aminoglycosides. J Antimicrob Chemother (1981) 0.95
Relation of the level of high-density lipoprotein subfractions to the presence and extent of coronary artery disease. Am J Cardiol (1992) 0.95
Cyclosporine treatment of severe ulcerative colitis during pregnancy. Am J Gastroenterol (1995) 0.95
Studies of the bioavailability of nitroglycerin from a transdermal therapeutic system (Nitroderm TTS). Eur J Clin Pharmacol (1984) 0.94
Changes in the apparent half life of gentamicin and tobramycin without detectable changes in creatinine clearance. Br J Clin Pharmacol (1979) 0.94
Temperature dependency of apparent cyclosporin A concentrations in plasma. Clin Chem (1983) 0.94
A comparison of cardiovascular effects of dobutamine and isoprenaline after open heart surgery. Br Heart J (1976) 0.93
Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation (1994) 0.93
Population pharmacokinetics of quinidine. Br J Clin Pharmacol (1991) 0.92
Beneficial effect of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function. Am J Cardiol (1992) 0.92
[Aortic valve insufficiency in Crohn disease]. Schweiz Med Wochenschr (1997) 0.91
Spontaneous multivessel coronary artery dissection in a pregnant woman treated successfully with stent implantation. Am J Med (1999) 0.91
Antihypertensive efficacy of ketanserin alone or in combination with a beta-blocker or a diuretic: the Swiss Ketanserin Study. J Cardiovasc Pharmacol (1987) 0.91
Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria. J Hepatol (2001) 0.90
Interaction between amiodarone and lidocaine. J Cardiovasc Pharmacol (1996) 0.90
Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure. J Clin Endocrinol Metab (1998) 0.89
Cardiovascular effects of a new inotropic drug in dog and normal man. Clin Pharmacol Ther (1976) 0.89
Serum concentration and antihypertensive effect of slow-release verapamil. J Cardiovasc Pharmacol (1982) 0.89
Once a day verapamil in essential hypertension. Br J Clin Pharmacol (1986) 0.88
Toxoplasmosis in heart transplant recipients. Eur J Clin Microbiol Infect Dis (1996) 0.88
Influence of thyroid function on theophylline kinetics. Clin Pharmacol Ther (1984) 0.88
Primary angiosarcoma of the pulmonary arteries: dynamic contrast-enhanced MRI. J Comput Assist Tomogr (1998) 0.87
Pretransplant malignancy in candidates and posttransplant malignancy in recipients of cardiac transplantation. Ann Oncol (1996) 0.87
Natural course of moderate cardiac allograft rejection (International Society for Heart Transplantation grade 2) early and late after transplantation. Circulation (1996) 0.87
Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. Am Heart J (1999) 0.86
Performance of Bayesian feedback to forecast lidocaine serum concentration: evaluation of the prediction error and the prediction interval. J Pharmacokinet Biopharm (1985) 0.86
Use of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections. Eur J Clin Microbiol (1986) 0.86
Determination of saquinavir in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl (1997) 0.86
Shifts in auditory brainstem response latencies following plasma-level-controlled aminoglycoside therapy. Eur Arch Otorhinolaryngol (1990) 0.86
Cyclosporin A used alone or in combination with low-dose steroids in cadaveric renal transplantation. Klin Wochenschr (1983) 0.85
Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo. J Cardiovasc Pharmacol (1990) 0.85
Changes in the QRS complex after aortic valve replacement. Br Heart J (1972) 0.85
Population pharmacokinetic parameters in patients treated with oral mexiletine. Eur J Clin Pharmacol (1982) 0.85
[On evaluation of the thoracic picture in acute pulmonary embolism]. Schweiz Med Wochenschr (1968) 0.85
Plasma levels of enalaprilat in chronic therapy of heart failure: relationship to adverse events. J Pharmacol Exp Ther (1999) 0.85
In vitro inhibition of midazolam and quinidine metabolism by flavonoids. Eur J Clin Pharmacol (1995) 0.84
Prognostic significance of oxygen uptake kinetics during low level exercise in patients with heart failure. Am J Cardiol (1999) 0.83
Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects. Clin Pharmacol Ther (1985) 0.83
Unusual electrocardiographic changes in Ebstein's anomaly. Br Heart J (1972) 0.83
Amiodarone inhibits arterial thrombus formation and tissue factor translation. Arterioscler Thromb Vasc Biol (2008) 0.83
Captopril and systemic lupus erythematosus syndrome. BMJ (1990) 0.83
Multicenter quality control study of amikacin assay for monitoring once-daily dosing regimens. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Ther Drug Monit (1995) 0.83
Oxygen uptake kinetics during low level exercise in patients with heart failure: relation to neurohormones, peak oxygen consumption, and clinical findings. Heart (1999) 0.83
Determination of dextromethorphan and dextrorphan in urine by high-performance liquid chromatography after solid-phase extraction. J Pharm Biomed Anal (1991) 0.83
Ruptured ventricular pseudoaneurysm. Heart (1998) 0.82
Rapid prediction of individual dosage requirements for lignocaine. Clin Pharmacokinet (1984) 0.82
Cyclosporine in human bone marrow transplantation. Serum concentration, graft-versus-host disease, and nephrotoxicity. Transplantation (1983) 0.82
[Hemiparesis and torsade de pointes under low-dose sotalol therapy]. Schweiz Med Wochenschr (1990) 0.82
Changes in QRS compledx after aortic valve replacement. Br Heart J (1971) 0.82
Infectious complications in 100 consecutive heart transplant recipients. Eur J Clin Microbiol Infect Dis (1994) 0.82
The role of β-blockers in the management of hypertension: an Asian perspective. Curr Med Res Opin (2011) 0.82
Rapid prediction of steady-state serum theophylline concentration in patients treated with intravenous aminophylline. Eur J Clin Pharmacol (1980) 0.81
Structure-effect relationships of amiodarone analogues on the inhibition of thyroxine deiodination. Eur J Clin Pharmacol (2000) 0.81
Myocardial amiodarone concentrations after short- and long-term treatment in patients with end-stage heart failure. Eur J Clin Pharmacol (1998) 0.81
[Relation of dose, serum concentration and side effects in intravenous aminophylline therapy]. Schweiz Med Wochenschr (1981) 0.80
Standardization of symbols in clinical pharmacology. Eur J Clin Pharmacol (1988) 0.80
[Course of obstructive arterial pulmonary hypertension]. Schweiz Med Wochenschr (1970) 0.80
[Prolonged coma caused by diazepam sedation in ventilated patients. Diagnostic and therapeutic use of the benzodiazepine antagonist Ro 15-1788]. Dtsch Med Wochenschr (1984) 0.80
Comparison of the pharmacodynamic effects of intravenous and oral propafenone. Clin Pharmacol Ther (1990) 0.80
Moxalactam in nosocomial infections with Serratia marcescens. Intensive Care Med (1985) 0.79
Circadian changes in the absorption and elimination of theophylline in patients with bronchial obstruction. Eur J Clin Pharmacol (1986) 0.79
[Diagnosis and therapy of cardiac tamponade. An analysis of 50 patients]. Schweiz Med Wochenschr (1981) 0.79
Homogeneous enzyme immunoassay for netilmicin. Antimicrob Agents Chemother (1982) 0.79
Pharmacodynamic comparison of oral and intravenous verapamil in atrial fibrillation. Clin Invest Med (1980) 0.79
Coronary ligation-reperfusion arrhythmia models in anesthetized rats and isolated perfused rat hearts concentration-effect relationships of lidocaine. J Pharmacol Methods (1986) 0.79
Review of the cardiovascular adversity of the calcium antagonist beta-blocker combination: implications for antihypertensive therapy. J Cardiovasc Pharmacol (1985) 0.78
Computer-assisted individualized lidocaine dosage: clinical evaluation and comparison with physician performance. Am Heart J (1987) 0.78
Netilmicin in the neonate: population pharmacokinetic analysis and dosing recommendations. Clin Pharmacol Ther (1991) 0.78
Determination of bupivacaine in plasma by high-performance liquid chromatography. Anesth Analg (1984) 0.78
[Cost effectiveness of bisoprolol in treatment of heart failure in Germany. An analysis based on the CIBIS-II study]. Med Klin (Munich) (2000) 0.78
Nonlinear kinetics of propafenone metabolites in healthy man. Eur J Clin Pharmacol (1990) 0.78